科倫藥業(002422.SZ)子公司擬引入投資者及進行股份制改造
格隆匯10月21日丨科倫藥業(002422.SZ)公佈，公司的全資子公司伊犁川寧生物技術有限公司(“伊犁川寧”)近年來發展狀況良好，生產狀態穩定滿產，在成本控制和環保處理方面具有較強的競爭力，未來市場發展空間較大。
公司積極響應國家資本市場的相關政策及趨勢，為進一步完善伊犁川寧的治理結構，建立長效激勵機制，拓展伊犁川寧的融資渠道，伊犁川寧擬實施員工持股計劃及引入外部優質投資者，並擬在上述工作完成後進行股份制改造。未來公司將擇機推動伊犁川寧走向資本市場，擴大其市場影響力，加速實現科倫藥業“三發驅動”戰略。
伊犁川寧主要從事醫藥中間體相關的研發、生產和銷售，主要產品為硫氰酸紅黴素、6-氨基青黴烷酸、7-氨基頭孢烷酸、7-氨基脱乙酰氧基頭孢烷酸以及青黴素工業鹽等。
伊犁川寧高度重視生產相關的創新與環保技術研發，建設有國家環境保護抗生素菌渣無害化處理與資源化利用工程技術中心，其“生物發酵抗生素生產尾氣處理技術集成及應用”榮獲新疆維吾爾自治區2016年科技進步一等獎。目前，伊犁川寧通過多年在行業內的深耕細作，已發展成為具有綜合競爭優勢的細分行業龍頭企業之一。
伊犁川寧擬實施員工持股計劃及引入外部優質投資者，並擬在上述工作完成後進行股份制改造。上述措施有助於提升伊犁川寧管理層及全體員工的責任心和敬業精神，激發其管理層推進企業快速發展的強大活力；能夠使伊犁川寧治理結構得到優化完善，提升其規範運作水平，增強核心競爭力。
未來，公司將推動伊犁川寧擇機走向資本市場，包括但不限於在境內或境外獨立上市，或者通過市場化債轉股、回購等方式實現投資者退出。此舉有助於公司及伊犁川寧融資渠道進一步拓展，幫助伊犁川寧強化其在產業中的領先優勢，並進一步做強做大。股份制改造可為伊犁川寧在符合有關法律、法規的條件下邁入資本市場奠定基礎，保障伊犁川寧可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
